Equities research analysts predict that Danaher Co. (NYSE:DHR) will announce sales of $4.5 billion for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Danaher’s earnings. The highest sales estimate is $4.54 billion and the lowest is $4.44 billion. Danaher reported sales of $5.79 billion in the same quarter last year, which indicates a negative year-over-year growth rate of 22.3%. The business is scheduled to issue its next quarterly earnings report on Monday, July 24th.

According to Zacks, analysts expect that Danaher will report full-year sales of $4.5 billion for the current financial year, with estimates ranging from $17.82 billion to $18.02 billion. For the next fiscal year, analysts anticipate that the company will post sales of $18.68 billion per share, with estimates ranging from $18.57 billion to $18.79 billion. Zacks’ sales averages are an average based on a survey of analysts that cover Danaher.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, April 20th. The conglomerate reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.01. Danaher had a net margin of 12.84% and a return on equity of 12.38%. The company had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.17 billion. During the same quarter in the previous year, the firm posted $1.08 earnings per share. Danaher’s revenue for the quarter was up 7.2% on a year-over-year basis.

Several research firms recently commented on DHR. Credit Suisse Group AG reaffirmed a “buy” rating and set a $93.00 target price on shares of Danaher in a report on Wednesday. William Blair reaffirmed an “outperform” rating on shares of Danaher in a report on Sunday, April 23rd. Cowen and Company reissued an “outperform” rating and issued a $90.00 price target on shares of Danaher in a report on Sunday, April 23rd. BTIG Research reissued a “buy” rating and issued a $92.00 price target on shares of Danaher in a report on Sunday, April 23rd. Finally, Zacks Investment Research lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Friday, April 21st. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $92.29.

In other Danaher news, SVP Angela S. Lalor sold 10,815 shares of Danaher stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $84.16, for a total value of $910,190.40. Following the completion of the transaction, the senior vice president now directly owns 39,020 shares of the company’s stock, valued at $3,283,923.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian W. Ellis sold 983 shares of Danaher stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $86.00, for a total transaction of $84,538.00. Following the completion of the transaction, the insider now directly owns 6,174 shares of the company’s stock, valued at $530,964. The disclosure for this sale can be found here. Over the last three months, insiders have sold 83,248 shares of company stock valued at $6,900,377. 12.60% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Jacobi Capital Management LLC boosted its position in shares of Danaher by 19.5% in the first quarter. Jacobi Capital Management LLC now owns 3,673 shares of the conglomerate’s stock valued at $315,000 after buying an additional 600 shares during the period. Palisades Hudson Asset Management L.P. purchased a new position in shares of Danaher during the first quarter valued at about $202,000. Pointe Capital Management LLC purchased a new position in shares of Danaher during the first quarter valued at about $348,000. Proficio Capital Partners LLC boosted its position in shares of Danaher by 92.3% in the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock valued at $105,000 after buying an additional 598 shares during the period. Finally, Teachers Retirement System of The State of Kentucky boosted its position in shares of Danaher by 86.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 138,087 shares of the conglomerate’s stock valued at $11,811,000 after buying an additional 64,061 shares during the period. 76.14% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Danaher Co. (DHR) Expected to Announce Quarterly Sales of $4.5 Billion” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/05/28/danaher-co-dhr-expected-to-announce-quarterly-sales-of-4-5-billion.html.

Shares of Danaher (NYSE:DHR) opened at 84.40 on Friday. The company has a market cap of $58.58 billion, a PE ratio of 25.72 and a beta of 1.00. The company has a 50 day moving average of $83.87 and a 200 day moving average of $82.54. Danaher has a 52 week low of $73.42 and a 52 week high of $88.01.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 30th will be given a dividend of $0.14 per share. The ex-dividend date is Wednesday, June 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.66%. Danaher’s dividend payout ratio (DPR) is currently 13.66%.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

12 Month Chart for NYSE:DHR

Get a free copy of the Zacks research report on Danaher (DHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Danaher Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Co. and related companies with MarketBeat.com's FREE daily email newsletter.